Lipid Profiles, Cardiovascular Disease Risk and Dyslipidemia in HIV Positive Patients on HAART at Machakos Level Five Hospital, Machakos County

Simple item page
dc.contributor.authorSyengo, Sarah Malinda
dc.contributor.authorMutai, Brian Kipngetich
dc.contributor.authorMenza, Nelson Chengo
dc.contributor.authorMathenge, Scholastica Gatwiri
dc.date.accessioned2023-07-24T07:24:43Z
dc.date.available2023-07-24T07:24:43Z
dc.date.issued2023
dc.descriptionArticleen_US
dc.description.abstractThis study determined the lipid profiles, dyslipidemia and cardiovascular disease risk as well as their associated risk factors in patients who are positive for the human immunodeficiency virus on antiretrovirals. The study adopted a cross-sectional design. Blood samples were analyzed to determine lipid profiles and dyslipidemia. Framingham Risk Score was used to determine cardiovascular disease risk. Descriptive statistics, Pearson’s Chi- Square test, bivariate and multivariable logistic regression analyses were performed. A p -value of ≤0.05 with corresponding 95% confidence interval was considered statistically significant. Participants using Protease Inhibitors were four times more likely to have a high Total Cholesterol to High Density Lipoprotein cholesterol ratio compared to those using Non- Nucleoside Reverse Transcriptase Inhibitors (OR =4.19, 95% CI: 1.03 - 17.02) p<0.05. Based on the Framingham risk score, 71.2%, 18.5%, 9.8% and 0.5% participants had low, moderate, moderately high and high cardiovascular disease risk respectively. Age, high-density lipoprotein, smoking and systolic pressure were significantly associated with a high Framingham Risk Score (p<0.001). Gender and duration on antiretrovirals were also significantly associated with high cardiovascular risk (p= 0.001). The overall prevalence of dyslipidemia was 74.5%. Age, systolic blood pressure and hypertension were significantly associated with dyslipidemia (p=0.005, p=0.049 and p<0.001) respectively. Gender, age, systolic pressure, hypertension, smoking and history of cardiovascular disease were significantly associated with cardiovascular disease risk (P= <0.001). The study offered information that will inform the policy makers on better approaches to employ in addressing the health outcomes for people living with the Human Immunodeficiency Virus under treatment with antiretrovirals.en_US
dc.identifier.citation: Syengo, S. M., Mutai, B. K., Menza, N. C., Mathenge, S. G. (2023). Lipid Profiles, Cardiovascular Disease Risk and Dyslipidemia in HIV Positive Patients on HAART at Machakos Level Five Hospital, Machakos County. J Chem Edu Res Prac, 7(2), 477-497.en_US
dc.identifier.urihttps://www.opastpublishers.com/open-access-articles/lipid-profiles-cardiovascular-disease-risk-and-dyslipidemia-in-hiv-positive-patients-on-haart-at-machakos-level-five-hos.pdf
dc.identifier.urihttp://ir-library.ku.ac.ke/handle/123456789/26353
dc.language.isoenen_US
dc.publisherOpast Publishing Groupen_US
dc.subjectDyslipidemiaen_US
dc.subjectIntegrase Inhibitoren_US
dc.subjectLipodystrophyen_US
dc.subjectMetabolic Syndromeen_US
dc.subjectNon-Nucleoside Reverse Transcriptase Inhibitoren_US
dc.subjectNuceloside Reverse Transcriptase Inhibitoren_US
dc.subjectProtease Inhibitoren_US
dc.titleLipid Profiles, Cardiovascular Disease Risk and Dyslipidemia in HIV Positive Patients on HAART at Machakos Level Five Hospital, Machakos Countyen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Lipid Profiles, Cardiovascular Disease Risk and Dyslipidemia in HIV Positive Patients on HAART at Machakos Level Five Hospital, Machakos County.pdf
Size:
624.5 KB
Format:
Adobe Portable Document Format
Description:
Full text Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
RP-Department of Medical Laboratory Sciences